US6486181B1ExpiredUtility

Human leukocutye 12-lipoxygenase and its role in the pathogenesis of disease states

59
Assignee: HOPE CITYPriority: Aug 28, 1992Filed: Oct 18, 2000Granted: Nov 26, 2002
Est. expiryAug 28, 2012(expired)· nominal 20-yr term from priority
Inventors:Jerry L. NadlerRama Natarajan
G01N 33/6893C12Q 1/26A61K 31/045A61K 31/195C12N 15/113C12Y 113/11031A61K 31/20C12N 9/0069A61K 31/575G01N 2333/90241A61K 31/155A61K 31/4439G01N 33/573C12Y 113/11012G01N 2800/042A61K 31/35A61K 31/44A61K 31/00
59
PatentIndex Score
3
Cited by
54
References
1
Claims

Abstract

The present invention relates to a method for inhibiting the etiology of disease in patients having a disease state caused by an excess of 12-lipoxygenase or its products. In particular, the invention provides for administration of a human leukocyte 12-lipoxygenase pathway inhibitor to inhibit disease etiology, to inhibit the proliferation of breast cancer and to increase insulin receptor phosphorylation in a patient having Type II diabetics.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
       1. A method for treating breast cancer by inhibiting or reducing vascular endothelial growth factor production in a non-diabetic human patient which comprises administering to said patient pioglitazone in an amount effective to retard or inhibit the expression of hl 12-lipoxygenase.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.